Its anticancer effects are linked to suppression of neoplastic transformation and bone metastasis in breast cancer via downregulation of receptor activator of NF-kappa B ligand (RANKL) and interleukin-8 (IL-8) [51,53], reversal of multidrug resistance by targeting multidrug resistance by downregulating MDR1 and P-glycoprotein (P-gp) in gastric cancer [51], and modulation of MAPK/ERK and ERK/PKA pathways in several cancer models [51,53]. Here, CXCL8 is linked to breast carcinoma.